Study find that COVID ARDS was associated with a low risk for possible or proven PCP: still true after dexamethasone use
Main Authors: | Patrick M. Honore, Sebastien Redant, Thierry Preseau, Keitiane Kaefer, Leonel Barreto Gutierrez, Sami Anane, Rachid Attou, Andrea Gallerani, David De Bels |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-02-01
|
Series: | Critical Care |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13054-022-03886-5 |
Similar Items
-
Is endocan correlated to ARDS severity or an epiphenomenon of thrombo-embolic disease in COVID
by: Patrick M. Honore, et al.
Published: (2021-12-01) -
Lung Targeted Lipopolymeric Microspheres of Dexamethasone for the Treatment of ARDS
by: Sabna Kotta, et al.
Published: (2021-08-01) -
Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS
by: Funda Terzi, et al.
Published: (2022-09-01) -
Indirect calorimetry is the gold standard to assess REE in ICU patients: some limitations to consider
by: Patrick M. Honore, et al.
Published: (2021-11-01) -
Dexamethasone for treatment of severe COVID-19, a surprise?
by: Hany Hasan Elsayed
Published: (2020-09-01)